Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease
Sans, Laia (Hospital del Mar (Barcelona, Catalunya))
Radosevic, Aleksandar (Hospital del Mar (Barcelona, Catalunya))
Quintian, Claudia (Institut d'Investigació Biomèdica Sant Pau)
Montañés, Rosario (Institut d'Investigació Biomèdica Sant Pau)
Gràcia, Silvia (Institut d'Investigació Biomèdica Sant Pau)
Vilaplana, Carles (Laboratori de Referència de Catalunya, Barcelona)
Mojal, Sergi (Institut Hospital del Mar d'Investigacions Mèdiques)
Ballarín Castan, José Aurelio (Institut d'Investigació Biomèdica Sant Pau)
Fernandez-Llama, Patricia (Institut d'Investigació Biomèdica Sant Pau)
Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau)
Pascual Santos, Julio (Hospital del Mar (Barcelona, Catalunya))
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	Height-adjusted total kidney volume (htTKV) is the best marker of disease progression in early autosomal dominant polycystic kidney disease (ADPKD) when renal function still remains normal. The usefulness of cystatin-C as a biomarker to assess renal function according to renal volume has not been studied in ADPKD patients. Observational and cross-sectional study of 62 ADPKD patients. htTKV, creatinine and cystatin-C estimated glomerular filtration rate (eGFR) were determined. Correlations between htTKV and eGFR were studied. A control group was used to determine the association between renal function differences and htTKV. htTKV significantly correlated with cystatin-C-eGFR (r = -0. 384, p = 0. 002) but not with creatinine-eGFR (r = -0. 225, p = 0. 078). With htTKV stratified into tertiles, a significant difference of cystatin-C-eGFR but not in creatinine-eGFR was detected in the third tertile when compared with the first tertile group (110. 0±22. 2 vs 121. 3±7. 2; p = 0. 023 and 101. 8±17. 2 vs 106. 9±15. 1; p = 0. 327 respectively). When cystatin-C-eGFR of the controls was used as the reference, htTKV above 605 ml/m identified with a 75% sensitivity and 84. 9% specificity those patients with a significant worse kidney function. However, this cut-off value could not be identified using creatinine-eGFR. Cystatin-C-eGFR but not creatinine-eGFR correlated with htTKV in ADPKD patients in early stages of the disease. Differences in cystatin-C-eGFR but not in creatinine-eGFR have been identified through htTKV tertiles. A htTKV above 605 ml/m is associated with a worse renal function only if cystatin-C-eGFR is used. Cystatin-C-eGFR should be studied in prospective studies of early stages of ADPKD to determine its usefulness as an early marker of disease progression.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	PloS one, Vol. 12 (march 2017) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0174583
PMID: 28346513

10 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles